{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:48Z","timestamp":1792404048322,"version":"4.4.0"},"publisher-location":"New York, NY","reference-count":18,"publisher":"Springer US","isbn-type":[{"value":"9781071635407","type":"print"},{"value":"9781071635414","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3541-4_6","type":"book-chapter","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:27:05Z","timestamp":1701390425000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Triazole Antifungal Quantification for Therapeutic Drug Monitoring in Serum by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS\/MS): Posaconazole, Voriconazole, Itraconazole, and Hydroxyitraconazole"],"prefix":"10.1007","author":[{"given":"Mark","family":"Girton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Tomsig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Bazydlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM et al (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162\u20131176","journal-title":"J Antimicrob Chemother"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20420986221143266","volume":"13","author":"S Chai","year":"2022","unstructured":"Chai S, Zhan JL, Zhao LM et al (2022) Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. Ther Adv Drug Saf 13:1\u201313","journal-title":"Ther Adv Drug Saf"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","volume":"27","author":"D Lev\u00eaque","year":"2006","unstructured":"Lev\u00eaque D, Nivoix Y, Jehl F et al (2006) Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 27:274\u2013284","journal-title":"Int J Antimicrob Agents"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1586\/eri.09.67","volume":"7","author":"MT Fera","year":"2009","unstructured":"Fera MT, La Camera E, De Sarro A (2009) New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti-Infect Ther 7:981\u2013998","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1128\/CMR.12.4.501","volume":"12","author":"MA Ghannoum","year":"1999","unstructured":"Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501\u2013517","journal-title":"Clin Microbiol Rev"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","volume":"50","author":"JB Gordien","year":"2009","unstructured":"Gordien JB, Pigneux A, Vigouroux S et al (2009) Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 50:932\u2013938","journal-title":"J Pharm Biomed Anal"},{"key":"6_CR7","unstructured":"Product information (Revised 2022) SPORANOX\u00ae (itraconazole). Available via Drugs@FDA database. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020083s065lbl.pdf. Accessed 16 June 2023"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.2147\/OTT.S223119","volume":"12","author":"K Li","year":"2019","unstructured":"Li K, Fang D, Xiong Z et al (2019) Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole. Onco Targets Ther 12:6875\u20136886","journal-title":"Onco Targets Ther"},{"key":"6_CR9","unstructured":"Product information (Revised 2022) NOXAFIL\u00ae (posaconazole). Available via Drugs@FDA database. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022003Orig1s027lbl.pdf. Accessed 16 June 2023"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"TJ Walsh","year":"2007","unstructured":"Walsh TJ, Raad I, Patterson TF et al (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2\u201312","journal-title":"Clin Infect Dis"},{"key":"6_CR11","unstructured":"Product information (Revised 2022) VFEND\u00ae (voriconazole). Available via Drugs@FDA database. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021266s053,021267s063,021630s042lbl.pdf. Accessed 16 June 2023"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/pgs.14.53","volume":"15","author":"JK Hicks","year":"2014","unstructured":"Hicks JK, Crews KR, Flynn P et al (2014) Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 15:1065\u20131078","journal-title":"Pharmacogenomics"},{"issue":"3","key":"6_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","volume":"16","author":"VJ Van De Velde","year":"1996","unstructured":"Van De Velde VJ, Van Peer AP, Heykants JJ et al (1996) Effect of food on the pharmacokinetics of a new hydroxypropyl-P-cyclodextrin formulation of itraconazole. Pharmacotherapy 16(3):424\u2013428","journal-title":"Pharmacotherapy"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1128\/AAC.00630-06","volume":"50","author":"JW Mouton","year":"2006","unstructured":"Mouton JW, Van Peer A, De Beule K et al (2006) Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 50:4096\u20134102","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim NH, Kim KH et al (2012) The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55:1080\u20131087","journal-title":"Clin Infect Dis"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","volume":"413","author":"S Pauwels","year":"2012","unstructured":"Pauwels S, Vermeersch P, Van Eldere J et al (2012) Fast and simple LC-MS\/MS method for quantifying plasma voriconazole. Clin Chim Acta 413:740\u2013743","journal-title":"Clin Chim Acta"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","volume":"47","author":"GJ Pennick","year":"2003","unstructured":"Pennick GJ, Clark M, Sutton DA et al (2003) Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 47:2348\u20132350","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cca.2011.09.042","volume":"413","author":"KY Beste","year":"2012","unstructured":"Beste KY, Burkhardt O, Kaever V (2012) Rapid HPLC-MS\/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clin Chim Acta 413:240\u2013245","journal-title":"Clin Chim Acta"}],"container-title":["Methods in Molecular Biology","Clinical Applications of Mass Spectrometry in Drug Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3541-4_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:32:00Z","timestamp":1701390720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3541-4_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"ISBN":["9781071635407","9781071635414"],"references-count":18,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3541-4_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"1 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}